EUCTR2018-003182-34-FR
Active, not recruiting
Phase 1
Randomized, double-blind, controlled clinical trial for comparison of continuous phenylephrine versus norepinephrine infusion for maintenance of hemodynamic stability during cesarean section under spinal anesthesia - PHENAD
CHR d'ORLEANS0 sites124 target enrollmentAugust 30, 2018
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CHR d'ORLEANS
- Enrollment
- 124
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Pregnancy \> 36 weeks of amenorrhea
- •\-Scheduled or semi\-urgent (interval between decision and delivery by caesarean section \>12hours) caesarean section under spinal anesthesia
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 124
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\-Extreme size (\<140cm,\> 180cm)
- •\-Weight less than 50kg
- •\- body mass index (BMI) \>40 kg/m2
- •\-Cardiovascular disease with use of cardiac medication
- •\-Active neurological disease.
- •\-antihypertensive drug.
- •\-severe pre\-eclampsia
- •\-American Society of Anesthesiologists physical status class \>3
- •\-Placenta accreta / percreta
- •\-Cesarean section scheduled under general anesthesia.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Double-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19COVID-related Acute Respiratory Distress SyndromeMedDRA version: 21.1Level: PTClassification code 10001052Term: Acute respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-002193-27-ESCristina Avendano-Sola20
Active, not recruiting
Phase 1
Effect of the administration of Hydroxychloroquine as prevention of COVID-19 infection in patients with biological treatment or with JAK inhibitorsQuimioprophylaxis of SARS-CoV-2 infection with hydroxyloquine (HCQ) in patients diagnosed with an immunomediated inflammatory disease who are following a treatment with biological agents and / or Jak inhibitorMedDRA version: 20.0Level: HLTClassification code 10021982Term: Inflammatory disorders following infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-001357-52-ESIDIVA800
Active, not recruiting
Phase 1
clinical study on the efficacy of infiltrative echo-guided therapy with hyaluronic acid (500-730 KDa) (HYALGAN®) versus saline solution in the conservative treatment of Achilles tendinopathy. Subjects will be randomly assigned to one of these two groups of treatment. Both evaluator and patients are unaware of the treatment assigned. In the open label extension, patients with persistent pain can receive a second cycle of Hyalgan.Achilles tendinopathyTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2013-004117-40-ITFidia Farmaceutici SpA54
Recruiting
Phase 3
A plant based Ayurvedic medicine used for the prevention and management of various risk factors responsible for occurrence of Coronary Heart Disease.CTRI/2015/01/005397Department of Science Technology1,000
Completed
Not Applicable
Traditional Chinese medicine for the management of aromatase inhibitor-associated musculoskeletal symptomsISRCTN06129599Beijing Municipal Science and Technology Commission (China)84